相关实验视频
Updated: Jul 19, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
21.9K
对于急性缺血性中风的静脉血栓溶解:从阿尔特酶到基酶
Nan Yang1, Hangil Lee2, Chuanjie Wu1
1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Brain circulation
|August 14, 2023
概括
对于急性缺血性中风的静脉内血栓溶解正在发展. 本综述涵盖了从阿尔特酶转变为特内克酶的情况,突出了中风治疗方面的进展.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在全球范围内,中风是导致死亡和残疾的主要原因.
- 使用高高的静脉 (IV) 血栓溶解是急性缺血性中风的标准治疗方法.
- 阿尔特普拉斯具有局限性,这促使人们寻找改进的血栓溶解剂.
研究的目的:
- 审查严重缺血性中风IV血栓溶解方面的进展.
- 讨论阿尔特酶的发展和从阿尔特酶向丁酶的过渡.
- 突出特内克特相对于高特的潜在益处.
主要方法:
- 关于中风IV血栓溶解的现有文献的小综述.
- 专注于血栓溶解疗法的演变.
- 对阿尔特和特内克的比较分析.
主要成果:
- 基体代表了对基体的进展.
- 过渡到基酶为中风治疗提供了潜在的好处.
- 进一步的研究支持基酶作为一个可行的替代品.
结论:
- 丁氏甲是治疗急性缺血性中风中的IV血栓溶解的阿尔特氏甲有前途的替代品.
- 转向基酶的转变意味着中风护理的进展.
- 优化血栓溶解药物治疗对于降低中风发病率和死亡率至关重要.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K
Acute Coronary Syndrome IV: Interprofessional Care
12
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12
Anticoagulant Drugs: Low-Molecular-Weight Heparins
753
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
753
Acute Coronary Syndrome I: Introduction
30
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
30

